 In this study, ganetespib will be administered twice weekly doses approximately 72 hours apart for 2 weeks, followed by surgery the day after the last dose of the study drug. There will be 3 dose levels, 80, 100 and 150mgm2 as highest dose. These doses were chosen based on the following considerations. In a Phase 1 study protocol 9090-01 investigating a twice-weekly ganetespib treatment schedule, doses up to 173 mgm2 were well tolerated, with manageable diarrhea and fatigue being the most common adverse events. Extensive correlative studies and pharmacokinetic PKpharmacodynamic PD modeling of preclinical data suggest that in humans the effective dose range for ganetespib is 70-150 mgm2. Therefore, 80 mgm2 is within the range of ganetespib effectiveness and 150 mgm2 twice weekly is a well-tolerated dose. 